La sclérose en plaques Défic Mot Situat Handicaps Asp Sociaux Psychol Médicaux Tech Législatifs Troubl Assoc Éditions Assoc Paralys Fr, pp.178-85, 2002. ,
Physiopathologie de la scl??rose en plaques, La Presse M??dicale, vol.39, issue.3, pp.341-349, 2010. ,
DOI : 10.1016/j.lpm.2009.12.001
Le point sur la scl??rose en plaques, Kin??sith??rapie, la Revue, vol.12, issue.125, pp.17-22, 2012. ,
DOI : 10.1016/j.kine.2012.04.005
Génétique de la Sclérose En Plaques: Héritabilité manquante et Charge génétique, 2013. ,
Sclérose en plaques : des formes bénignes aux formes rapidement invalidantes. Médecine, pp.162-168, 2007. ,
Age at disability milestones in multiple sclerosis, Brain, vol.129, issue.3, pp.595-605, 2006. ,
DOI : 10.1093/brain/awh714
La sclérose en plaques, John Libbey Eurotext, 1997. ,
25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis, Multiple Sclerosis, vol.11, issue.3, pp.266-71, 2005. ,
DOI : 10.1191/1352458505ms1157oa
Vitamin D intake and incidence of multiple sclerosis, Neurology, vol.62, issue.1, pp.60-65, 2004. ,
DOI : 10.1212/01.WNL.0000101723.79681.38
La scl??rose en plaques, Actualit??s Pharmaceutiques Hospitali??res, vol.5, issue.19, pp.14-23, 2009. ,
DOI : 10.1016/S1769-7344(09)70013-7
Implications of dietary salt intake for multiple sclerosis pathogenesis, Multiple Sclerosis Journal, vol.18, issue.2, pp.133-142 ,
DOI : 10.1136/bmj.39147.604896.55
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1, Nature, vol.16, issue.7446, pp.513-520, 2013. ,
DOI : 10.1038/nature11984
Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells, Nature, vol.197, issue.7446, pp.518-540, 2013. ,
DOI : 10.1038/nature11868
Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated RetroViral element) envelope protein in patients with multiple sclerosis, Journal of Neuroimmunology, vol.160, issue.1-2, pp.195-203, 2005. ,
DOI : 10.1016/j.jneuroim.2004.10.019
Vaccinations and the Risk of Relapse in Multiple Sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.319-345, 2001. ,
DOI : 10.1056/NEJM200102013440501
Les maladies neurologiques à travers les études pan-génomiques (Genome Wide Association Studies-GWAS), Lett L?, vol.62, p.12, 2011. ,
Fatigue in multiple sclerosis and its relationship to depression and neurologic disability, Multiple Sclerosis, vol.6, issue.3, pp.181-186, 2000. ,
DOI : 10.1191/135245800701566052
Traitement de la sclérose en plaques: nouveautés et complications, Neurologie, vol.384, issue.17, pp.940-943, 2013. ,
Sclérose en plaques : traitements d'aujourd'hui et de demain. Médecine, Feb, vol.13, issue.2, pp.61-67, 2007. ,
Une recherche dynamique permet d'envisager des avancées thérapeutiques significatives, 2009. ,
La sclérose en Plaques les traitements, Réseau Rhône Alpes SEP ,
Overview of azathioprine treatment in multiple sclerosis. The Lancet, pp.1051-1056, 1991. ,
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis, Annals of Neurology, vol.29, issue.1, pp.30-40, 1995. ,
DOI : 10.1002/ana.410370108
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN), The Lancet, vol.359, issue.9316, pp.1453-60, 2002. ,
DOI : 10.1016/S0140-6736(02)08430-1
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, pp.898-904, 2000. ,
DOI : 10.1056/NEJM200009283431301
Placebo-controlled multicentre randomised trial of interferon ?-1b in treatment of secondary progressive multiple sclerosis. The Lancet, pp.1491-1498, 1998. ,
Traitements actuels de la sclérose en plaques. Presse Médicale, pp.381-389, 2010. ,
Les nouvelles formes m??dicamenteuses orales dans la scl??rose en plaques, Actualit??s Pharmaceutiques, vol.54, issue.547, pp.41-46 ,
DOI : 10.1016/j.actpha.2015.03.033
Sclérose en Plaques: les nouveaux traitements, 2015. ,
Statins as potential therapeutic agents in neuroinflammatory disorders, Current Opinion in Neurology, vol.16, issue.3, pp.393-401, 2003. ,
DOI : 10.1097/00019052-200306000-00021
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study, The Lancet Neurology, vol.8, issue.3, pp.244-53, 2009. ,
DOI : 10.1016/S1474-4422(09)70017-1
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial, The Lancet, vol.373, issue.9665, pp.732-740, 2009. ,
DOI : 10.1016/S0140-6736(09)60442-6
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis, Multiple Sclerosis Journal, vol.192, issue.4, pp.425-458, 2004. ,
DOI : 10.1093/brain/124.5.962
Décrire: entretien et observation, J.-M, 2009. ,
Randomized, comparative study of interferon ??-1a treatment regimens in MS: The EVIDENCE Trial, Neurology, vol.59, issue.10, pp.1496-506, 2002. ,
DOI : 10.1212/01.WNL.0000034080.43681.DA